Keyword: Ipsen


Ipsen and Marengo in Cancer Collaboration

08.08.2022 -

French biopharma Ipsen and US-based Marengo Therapeutics have formed a strategic partnership that aims to advance two of Marengo’s preclinical immuno-oncology candidates...


Ipsen in Talks to Sell Consumer Healthcare to Mayoly Spindler

16.02.2022 -

French pharma Ipsen has entered into exclusive negotiations for the sale of its global consumer healthcare business to compatriot firm Mayoly Spindler. The move, said...


Ipsen Pays $1.3 Billion for Clementia

05.03.2019 - French drugmaker Ipsen has agreed to buy Canada’s Clementia Pharmaceuticals, boosting its rare disease portfolio. Ipsen will pay $1.04 billion for the clinical-stage biotechnology...

Plant Construction & Process Technology

The Chemical Footprint in Pharma

26.04.2017 - The chemical industry is the most important supplier of the pharmaceutical industry, but it can´t keep pace with the economic strength and R&D intensity of pharma. This underlines...


Sanofi to Sell Five OTC Products to Ipsen

15.02.2017 - French pharmaceutical producer Sanofi has agreed to sell five consumer healthcare products in certain European territories to compatriot drugmaker Ipsen for €83 million. The cash...


Ipsen Takes Merrimack’s Oncology Assets

12.01.2017 - French drugmaker Ipsen has signed a definitive agreement to buy the global oncology assets of US-based Merrimack Pharmaceuticals in a deal worth potentially more than $1 billion...


Ipsen Pays $855 Million for Exelixis’ Cancer Drug

07.03.2016 - French pharmaceutical company Ipsen is paying up to $855 million for the rights to Exelixis’ cancer drug Cabozantinib. Under the deal, Exelixis gains exclusive commercialization...


Novasep Appoints Two New Members to its Executive Committee

11.05.2015 - Novasep announced two new appointments to its executive committee (COMEX). Pierre-Louis Mikus joins as chief legal officer. Bertrand Waymel is promoted to group human resources...